Overview |
bs-7601R |
IKKi (Thr501) Polyclonal Antibody |
WB, ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC) |
Human, Cow, Rabbit |
Specifications |
Unconjugated |
Rabbit |
KLH conjugated synthetic phosphopeptide derived from human IKKi/IKKe around the phosphorylation site of Thr501 [LR(p-T)LA] |
Thr501 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
Target |
9641 |
Cytoplasm, Nucleus |
IKKi/IKKe phospho T501; IKKi/IKKe phospho Thr501; p-IKKE Thr501; p-IKKE T501; IKKi/IKKe; I kappa B kinase epsilon; IkBKE; IKBKE protein; IKK E; IKK i; IKK-i; IKK related kinase epsilon; IKKE; IKK-E; IKKepsilon; IKKI; Inducible I kappa B kinase; inducible IkappaB kinase; Inhibitor of kappa light polypeptide gene enhancer in B cells kinase epsilon; Inhibitor of nuclear factor kappa B kinase subunit epsilon; KIAA0151; MGC125294; MGC125295; MGC125297; IKKE_HUMAN; I-kappa-B kinase epsilon; IKK-epsilon; Inducible I kappa-B kinase. |
IKBKE is a noncanonical I-kappa-B (see MIM 164008) kinase (IKK) that is essential for regulating antiviral signaling pathways. IKBKE has also been identified as a breast cancer (MIM 114480) oncogene and is amplified and overexpressed in over 30% of breast carcinomas and breast cancer cell lines (Hutti et al., 2009 [PubMed 19481526]).[supplied by OMIM, Oct 2009]. |
Application Dilution |
WB |
1:300-5000 |
ELISA |
1:500-1000 |
IHC-P |
1:200-400 |
IHC-F |
1:100-500 |
IF(IHC-P) |
1:50-200 |
IF(IHC-F) |
1:50-200 |
IF(ICC) |
1:50-200 |